Public investments in the development of GeneXpert molecular diagnostic technology.

ABSTRACT:

Background

The GeneXpert diagnostic platform from the US based company Cepheid is an automated molecular diagnostic device that performs sample preparation and pathogen detection within a single cartridge-based assay. GeneXpert devices can enable diagnosis at the district level without the need for fully equipped clinical laboratories, are simple to use, and offer rapid results. Due to these characteristics, the platform is now widely used in low- and middle-income countries for diagnosis of diseases such as TB and HIV. Assays for SARS-CoV-2 are also being rolled out. We aimed to quantify public sector investments in the development of the GeneXpert platform and Cepheid's suite of cartridge-based assays.

Methods

Public funding data were collected from the proprietor company'

SUBMITTER: Gotham D 

PROVIDER: S-EPMC8407584 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature